Antibody-drug conjugates (ADCs) are a new class of highly potent biopharmaceuticals that combine the specificity of monoclonal antibodies with the cytotoxicity of chemical drugs to improve cancer treatment. The mechanism of ADCs involves binding to cell surface antigens, internalization, and targeted drug release leading to cell death, while maintaining high tumor selectivity and low immunogenicity. Creative Biolabs offers comprehensive ADC development services, including antibody screening, custom synthesis, and in vivo analysis, to accelerate the ADC development process.

1. Basic knowledge of
Antibody-Drug
Conjugates(ADC)
Creative Biolabs
2018.01

2. Where is the story begin?
Cancer treatment
Surgical resection
Chemotherapy
Radiotherapy
Immunotherapy
Monoclonal
Antibody
Deliver cytotoxic
chemical drug with
tumor cell specificity
Antibody-Drug
Conjugates
mAb: High-specificity and anti-tumor activity but not sufficiently cytotoxicity
Chemical Drug: Potent cell killing activity but too toxic to be used on their own
mAb + Chemical Drug = Antibody Drug Conjugates

3. ADCs are new class of highly potent
biopharmaceutical drug composed of an
antibody linked via a chemical linker to a
biologically active drug or cytotoxic
compound.
 A highly selective monoclonal antibody
 A linker
 A potent cytotoxic agent
What are Antibody Drug Conjugates (ADC)？

4. 1. ADC binding to cell surface antigen;
2. ADC internalization;
3. Transport into lysosome;
4. Degradation in lysosome;
5. Drug release and activation;
6. Cytotoxicity effect
The Mechanism of Action of Antibody Drug Conjugates (ADC)

5. High tumor cell
selectivity
Low immunogenicity
Appropriate stability
Effective cytotoxicity
Homogeneous
Controllable release
The key features of Antibody Drug Conjugates (ADC)

6. Tumor type & Antigen expression Impact of Ig format
IgG
IgG1 IgG2 IgG3 IgG4
• Most commonly used
• Inherent effector function
• Also used but lack of
Fc-mediated function
ADC antibody
candidate
Antibody Properties

7. Linker Strategy

8. Conjugation Strategy

9. Microtubule Disruptor
Drug Payload Type
DNA Binding Agent

10. Antigen
mAb
Linker
Drug
• High tumor cell selectivity
• High target cell expression rate
• Easy for internalization
• High sensitivity and specificity
• Well characterized PK/PD
• Non-antibody angent
• Novel strategy
• Site specific conjugation
• Higher loading capacity
• Cytotoxic nature products
• Novel mechanism of action
A
D
C
• Overcoming the resistance
• Effective tumor penetration
• Increasing homogeneous
• More characterization method
Future Directions

11. ADC Service of Creative Biolabs
ADC antibody
screening
Custom
synthesis
Antibody design
&
conjugation
ADC in vivo
analysis
Antibody-based
probs
ADC manufacturing
01
02
03
0405
06
07
ADC in vitro
analysis
PtLnX™
With our integrated global resources in all aspects, our one-
stop ADC development services will provide you with a
platform that could exponentially speed up the process of ADC
development, from ADC formulation to clinical evaluation, and
ultimately promote science for the cause of a better tomorrow.

12. Address: 45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-871-5806
Fax: 1-631-614-7828
Email: info@creative-biolabs.com
Web: www.creative-biolabs.com/car-t/